Fig. 5From: Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitorsKaplan–Meier plot representing the progression-free survival probability for patients with advanced melanoma in whom BRAF V600mut ctDNA became undetectable after initiation of a BRAF inhibitor containing treatment regimen (solid line), and for patients in whom BRAF V600mut ctDNA remained detectable during follow-up (dashed line)Back to article page